Cognition Therapeutics (CGTX) Operating Income (2020 - 2026)
Cognition Therapeutics (CGTX) reported Operating Income of -$8.8 million for Q1 2026, up 35.99% year-over-year from -$6.5 million in Q1 2025, and up 35.51% on a QoQ basis from -$13.7 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Operating Income data on file, last reported at -$8.8 million in Q1 2026.
- Quarterly Operating Income rose 35.99% year-over-year to -$8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.8 million (up 20.13% YoY) and the FY2025 annual result came in at -$47.8 million, up 11.43% from the prior year.
- Operating Income improved to -$8.8 million in Q1 2026 per CGTX's latest filing, from -$13.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$6.4 million in Q3 2025 and bottomed at -$15.2 million in Q4 2023.
- The 5-year median for Operating Income is -$13.1 million (2022), against an average of -$12.0 million.
- The widest annual swing landed in 2022, when Operating Income sank 141.72%; it then jumped 55.92% in 2025.
- Tracing CGTX's Operating Income over 5 years: stood at -$9.3 million in 2022, then plunged by 63.32% to -$15.2 million in 2023, then rose by 29.4% to -$10.7 million in 2024, then retreated by 27.49% to -$13.7 million in 2025, then jumped by 35.51% to -$8.8 million in 2026.
- Per Business Quant, the three latest CGTX Operating Income figures stand at -$8.8 million (Q1 2026), -$13.7 million (Q4 2025), and -$6.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 642.90 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -8.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.82 Mn |
| Dec 31, 2025 | -13.67 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Mar 31, 2025 | -13.78 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -14.46 Mn |
| Jun 30, 2024 | -14.68 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Dec 31, 2023 | -15.19 Mn |
| Sep 30, 2023 | -14.75 Mn |
| Jun 30, 2023 | -11.82 Mn |
| Mar 31, 2023 | -8.97 Mn |
| Dec 31, 2022 | -9.30 Mn |
| Sep 30, 2022 | -12.63 Mn |
| Mar 31, 2022 | -9.41 Mn |
| Dec 31, 2021 | -11.81 Mn |
| Sep 30, 2021 | -5.22 Mn |
| Dec 31, 2020 | -4.12 Mn |
| Sep 30, 2020 | -4.46 Mn |